Literature DB >> 15817915

Diagnosis of GH deficiency in the transition period: accuracy of insulin tolerance test and insulin-like growth factor-I measurement.

Mohamad Maghnie1, Gianluca Aimaretti, Simonetta Bellone, Gianni Bona, Jaele Bellone, Roberto Baldelli, Carlo de Sanctis, Luigi Gargantini, Roberto Gastaldi, Lucia Ghizzoni, Andrea Secco, Carmine Tinelli, Ezio Ghigo.   

Abstract

OBJECTIVE: A consensus exists that severe growth hormone deficiency (GHD) in adults is defined by a peak GH response to insulin-induced hypoglycemia (insulin tolerance test, ITT) of less than 3 microg/l based on a cohort of subjects with a mean age of 45 years. DESIGN AND METHODS: By considering one of the following two criteria for the diagnosis of probable permanent GHD, i.e. the severity of GHD (suggested by the presence of multiple pituitary hormone deficiencies (MPHD)) or the magnetic resonance (MR) imaging identification of structural hypothalamic-pituitary abnormalities, 26 patients (17 males, 9 females, mean age 20.8 +/- 2.3 years, range 17-25 years) were selected for re-evaluation of the GH response to ITT and their IGF-I concentration. Eight subjects had isolated GHD (IGHD) and 18 had MPHD. Normative data for peak GH were obtained after ITT in 39 healthy subjects (mean age 21.2 +/- 4.4 years, range 15.1-30.0 years) and the reference range for IGF-I was calculated using normative data from 117 healthy individuals.
RESULTS: Mean peak GH response to ITT was significantly lower in the 26 patients (1.8+/-2.0 microg/l, range 0.1-6.1 microg/l) compared with the 39 controls (18.5 +/- 15.5 microg/l, range 6.1-84.0 microg/l; P < 0.0001). One subject with septo-optic dysplasia had a peak GH response of 6.1 microg/l that overlapped the lowest peak GH response obtained in normal subjects. There was an overlap for IGF-I SDS between subjects with IGHD and MPHD, as well as with normal controls. The diagnostic accuracy of a peak GH response of 6.1 microg/l showed a 96% sensitivity with 100% specificity. The maximum diagnostic accuracy with IGF-I SDS was obtained with a cut-off of -1.7 SDS (sensitivity 77%, specificity 100%) while an IGF-I < or = - 2.0 SDS showed a sensitivity of 62%.
CONCLUSION: Our data show that the cut-off value of the peak GH response to ITT of less than 3 microg/l or 5 microg/l and of IGF-I of less than -2.0 SDS are too restrictive for the diagnosis of permanent GH deficiency in the transition period. We suggest that permanent GHD could be investigated more accurately by means of an integrated analysis of clinical history, the presence of MPHD, IGF-I concentration and the MR imaging findings of structural hypothalamic-pituitary abnormalities.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15817915     DOI: 10.1530/eje.1.01873

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  17 in total

Review 1.  Growth hormone treatment in adults with growth hormone deficiency: the transition.

Authors:  M E Molitch
Journal:  J Endocrinol Invest       Date:  2011-01-26       Impact factor: 4.256

2.  Diagnosis: a reappraisal of the diagnosis of growth hormone deficiency.

Authors:  Gudmundur Johannsson
Journal:  Nat Rev Endocrinol       Date:  2010-04       Impact factor: 43.330

3.  Growth hormone treatment of adolescents with growth hormone deficiency (GHD) during the transition period: results of a survey among adult and paediatric endocrinologists from Italy. Endorsed by SIEDP/ISPED, AME, SIE, SIMA.

Authors:  G Aimaretti; R Attanasio; S Cannavò; M C Nicoletti; R Castello; C Di Somma; P Garofalo; L Iughetti; S Loche; M Maghnie; L Mazzanti; G Saggese; M Salerno; G Tonini; V Toscano; S Zucchini; M Cappa
Journal:  J Endocrinol Invest       Date:  2014-11-02       Impact factor: 4.256

Review 4.  Growth hormone deficiency in the transition period: body composition and gonad function.

Authors:  G Balercia; L Giovannini; F Paggi; M Spaziani; N Tahani; M Boscaro; A Lenzi; A Radicioni
Journal:  J Endocrinol Invest       Date:  2011-06-21       Impact factor: 4.256

5.  Experience of a Pituitary Clinic for US Military Veterans With Traumatic Brain Injury.

Authors:  Jonathan Lee; Lindsey J Anderson; Dorota Migula; Kevin C J Yuen; Lisa McPeak; Jose M Garcia
Journal:  J Endocr Soc       Date:  2021-01-25

6.  Should Pediatric Endocrinologists Consider More Carefully When to Perform a Stimulation Test?

Authors:  Arturo Penco; Benedetta Bossini; Manuela Giangreco; Viviana Vidonis; Giada Vittori; Nicoletta Grassi; Maria Chiara Pellegrin; Elena Faleschini; Egidio Barbi; Gianluca Tornese
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-22       Impact factor: 5.555

7.  High prevalence of chronic pituitary and target-organ hormone abnormalities after blast-related mild traumatic brain injury.

Authors:  Charles W Wilkinson; Kathleen F Pagulayan; Eric C Petrie; Cynthia L Mayer; Elizabeth A Colasurdo; Jane B Shofer; Kim L Hart; David Hoff; Matthew A Tarabochia; Elaine R Peskind
Journal:  Front Neurol       Date:  2012-02-07       Impact factor: 4.003

8.  Approach to the Patient: Management of Pituitary Hormone Replacement Through Transition.

Authors:  Manuela Cerbone; Harshini Katugampola; Helen L Simpson; Mehul T Dattani
Journal:  J Clin Endocrinol Metab       Date:  2022-06-16       Impact factor: 6.134

9.  Influence of biochemical diagnosis of growth hormone deficiency on replacement therapy response and retesting results at adult height.

Authors:  Giulia Rodari; E Profka; F Giacchetti; I Cavenaghi; M Arosio; C Giavoli
Journal:  Sci Rep       Date:  2021-07-15       Impact factor: 4.379

10.  The Challenge of Growth Hormone Deficiency Diagnosis and Treatment during the Transition from Puberty into Adulthood.

Authors:  Elena Inzaghi; Stefano Cianfarani
Journal:  Front Endocrinol (Lausanne)       Date:  2013-03-20       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.